Natera (NTRA) shares are surging 13.41% in pre-market trading on Friday, following the release of the company's impressive second-quarter 2025 financial results, an upgraded full-year outlook, and a series of analyst price target increases. The genetic testing company significantly outperformed market expectations, demonstrating robust growth across its key business segments.

Natera reported total revenues of $546.6 million for Q2 2025, marking a substantial 32.2% increase from the same period last year and handily beating analyst estimates of $476.3 million. The strong performance was primarily driven by a 32.3% rise in product revenues, which reached $544.4 million. The company processed approximately 853,100 tests during the quarter, up from 760,300 tests in Q2 2024, with oncology testing volumes showing particularly impressive growth.

Adding to the optimism, Natera raised its full-year 2025 revenue guidance to a range of $2.02 billion to $2.10 billion, up from the previous forecast of $1.94 billion to $2.02 billion. This upward revision signals management's confidence in continued strong adoption of its core product lines and ability to capitalize on market opportunities. The company's improved profitability metrics, with gross margin increasing to 63.4% from 58.8% in the previous year, further bolstered investor confidence. In response to these strong results, several analysts have raised their price targets for Natera, including JP Morgan (to $210 from $200), Barclays (to $210 from $190), and BTIG (to $200 from $195), reflecting a bullish outlook on the company's future prospects in the rapidly evolving field of genetic testing and precision medicine.